Cargando…

Focal therapy for localized prostate cancer – Current status

Focal therapy (FT) has recently gained popularity for the treatment of localized prostate cancer (PCa). FT achieves cancer control by targeting the lesions or the regions of the cancer and avoids damage to the surrounding tissues thus minimizing side effects which are common to the radical treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Atluri, Shrikanth, Mouzannar, Ali, Venkatramani, Vivek, Parekh, Dipen J., Nahar, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796757/
https://www.ncbi.nlm.nih.gov/pubmed/35136289
http://dx.doi.org/10.4103/iju.iju_166_21
_version_ 1784641396706115584
author Atluri, Shrikanth
Mouzannar, Ali
Venkatramani, Vivek
Parekh, Dipen J.
Nahar, Bruno
author_facet Atluri, Shrikanth
Mouzannar, Ali
Venkatramani, Vivek
Parekh, Dipen J.
Nahar, Bruno
author_sort Atluri, Shrikanth
collection PubMed
description Focal therapy (FT) has recently gained popularity for the treatment of localized prostate cancer (PCa). FT achieves cancer control by targeting the lesions or the regions of the cancer and avoids damage to the surrounding tissues thus minimizing side effects which are common to the radical treatment, such as urinary continence and sexual function, and bowel-related side effects. Various ablative methods are used to deliver energy to the cancerous tissue. We review the different modalities of treatment and the current state of FT for PCa.
format Online
Article
Text
id pubmed-8796757
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-87967572022-02-07 Focal therapy for localized prostate cancer – Current status Atluri, Shrikanth Mouzannar, Ali Venkatramani, Vivek Parekh, Dipen J. Nahar, Bruno Indian J Urol Review Article Focal therapy (FT) has recently gained popularity for the treatment of localized prostate cancer (PCa). FT achieves cancer control by targeting the lesions or the regions of the cancer and avoids damage to the surrounding tissues thus minimizing side effects which are common to the radical treatment, such as urinary continence and sexual function, and bowel-related side effects. Various ablative methods are used to deliver energy to the cancerous tissue. We review the different modalities of treatment and the current state of FT for PCa. Wolters Kluwer - Medknow 2022 2022-01-01 /pmc/articles/PMC8796757/ /pubmed/35136289 http://dx.doi.org/10.4103/iju.iju_166_21 Text en Copyright: © 2022 Indian Journal of Urology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Atluri, Shrikanth
Mouzannar, Ali
Venkatramani, Vivek
Parekh, Dipen J.
Nahar, Bruno
Focal therapy for localized prostate cancer – Current status
title Focal therapy for localized prostate cancer – Current status
title_full Focal therapy for localized prostate cancer – Current status
title_fullStr Focal therapy for localized prostate cancer – Current status
title_full_unstemmed Focal therapy for localized prostate cancer – Current status
title_short Focal therapy for localized prostate cancer – Current status
title_sort focal therapy for localized prostate cancer – current status
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796757/
https://www.ncbi.nlm.nih.gov/pubmed/35136289
http://dx.doi.org/10.4103/iju.iju_166_21
work_keys_str_mv AT atlurishrikanth focaltherapyforlocalizedprostatecancercurrentstatus
AT mouzannarali focaltherapyforlocalizedprostatecancercurrentstatus
AT venkatramanivivek focaltherapyforlocalizedprostatecancercurrentstatus
AT parekhdipenj focaltherapyforlocalizedprostatecancercurrentstatus
AT naharbruno focaltherapyforlocalizedprostatecancercurrentstatus